Subscribe Login
A-Brands

Johnson & Johnson 2019 Revenue Forecast Misses Expectations

Johnson & Johnson on Tuesday forecast 2019 sales that fell short of analysts' estimates after reporting better-than-expected fourth-quarter profit and revenue.

The better-than-expected 2019 sales in the range of $80.4 billion to $81.2 billion, compared with the average analyst estimate of $82.69 billion, according to IBES data from Refinitiv.

Performance

Overall fourth-quarter sales rose to $20.39 billion from $20.20 billion, also topping the Wall Street estimate of $20.20 billion.

Pharmaceuticals sales rose 5.3% to $10.19 billion in the fourth quarter, led by Crohn's disease treatment Stelara. Analysts had expected revenue of $10.08 billion for the unit.

The company posted net profit of $3.04 billion, or $1.12 per share, for the fourth quarter, compared with a loss of $10.71 billion, or $3.99 per share, a year earlier, when it recorded a $13.6 billion charge related to changes to the U.S. tax law.

Excluding items, the company earned $1.97 per share, beating analysts' average estimate of $1.95 per share.

The company said it expected adjusted 2019 profit in the range of $8.50 per share to $8.65 per share, compared with analysts' expectation of $8.60 per share.

News by Reuters, edited by Checkout. Click subscribe to sign up for the Checkout print edition.

Stay Connected With Our Weekly Newsletter

Processing your request...

Thanks! please check your email to confirm your subscription.

LIMITED TIME OFFER: 20% Off Our Premium Subscription
Enjoy full access to all website and app content, our weekly email news digest, and to Checkout Magazine 12 times a year (including our Top 100 Brands 2022 edition).
LIMITED TIME OFFER: 20% Off Our Premium Subscription
LIMITED TIME OFFER: 20% Off Our Premium Subscription
Enjoy full access to all website and app content, our weekly email news digest, and to Checkout Magazine 12 times a year (including our Top 100 Brands 2022 edition).
LIMITED TIME OFFER: 20% Off Our Premium Subscription